Medivir AB (SSE:MVIR B) lost SEK4.60 (12%) to SEK34.05 on Monday after announcing it will delay to 2019 the start of a Phase III trial of remetinostat in early stage cutaneous T-cell lymphoma (CTCL). The company, which had previously guided that the trial would start this year, said the delay is due to continuing discussion with FDA on the trial’s design.
Remetinostat is a topical gel formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor.
Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp.